Leadership

Steve Yang, Ph.D.

Co-CEO

A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi AppTec, Dr. Yang was Vice President and Head of Asia and Emerging Markets IMED at AstraZeneca, and served as Vice President and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic management group. Dr. Yang received his Ph.D. in pharmaceutical chemistry from the University of California, San Francisco.

Xuanjia Peng, Ph.D.

Senior Vice President, Head of WuXi Testing, Head of WuXi Biology, Head of WuXi AppTec Automation Department

Since joining WuXi AppTec, Dr. Xuanjia Peng has successful track records in leading business and operation units spanning drug discovery hit generation, chemistry catalog, chemistry service operation, and medicinal chemistry service. Dr. Peng received his Ph.D. in Organic Chemistry from Lanzhou University.

Letian Kuai, Ph.D.

Vice President, Chief Scientific Officer of WuXi Biology , Head of In Vitro Biology Unit (IVBU)

Letian Kuai received his Ph.D. in biochemistry from the University of Rochester in 2004, followed by post-doctoral training at the Broad Institute of MIT and Harvard. At a leading pharmaceutical company, he became a key innovator and contributor to the development of DNA-Encoded Library (DEL) technology. Dr. Kuai joined WuXi AppTec HitS in 2018, and built an integrated suite of high-quality and customizable solutions, with capabilities spanning protein and antibody sciences, DNA-encoded libraries, biophysics, and structural biology.

Peiyuan Lin, Ph.D.

Senior Vice President, Head of Expert Team in Wuxi Biology

Peiyuan Lin joined HD Biosciences (a WuXi AppTec subsidiary company) as Senior Vice President in 2008, leading R&D efforts in drug discovery. Dr. Lin earned her Ph.D. in molecular pharmacology from the University of Cincinnati in 1988. Since then, she has over 30 years of extensive knowledge and experience in drug discovery working in both pharmaceutical drug discovery (Roche and GSK) and the CRO industry.

Qingyang Gu, Ph.D.

Vice President, Head of In Vivo Pharmacology Unit (IVPU)

Dr. Qingyang Gu joined WuXi AppTec in 2012. He has been dedicated to working in the fields of tumor biology, anti-tumor therapeutics development, and translational medicine for more than two decades, in which he has gained a wealth of experience and expertise in biomedical sciences and team management.

Mahnaz Arjomand, MS, MBA

Executive Director and Head of Business Development, WuXi Biology, North America

Mahnaz Arjomand is the Executive Director and Head of Business Development for WuXi Biology, North America. Mahnaz has been with WuXi AppTec since 2016 and has more than 20 years of experience in technical sales and business development in the biotech industry and various CROs specializing in toxicology, bioanalytical, medical device, DMPK, and research services.

Dave Madge, Ph.D.

Vice President, EU and Israel BD Head

Over 20 years’ experience working within academia, biotech and CRO companies. Dave Madge is the former VP Research at Xention, founder of NCE Discovery (now Domainex) and a member of the integrated biomedical research group at University College London. Dave started his career at the Wellcome Foundation and received his Ph.D. in chemistry from Imperial College, London.

Take your research to the next level